Brief: Pharmather receives US FDA approval goal date for Ketamine
11/03/2025 13:35
March 11 (Reuters) - Pharmather Holdings Ltd PHRM.CD: PHARMATHER RECEIVES US FDA APPROVAL GOAL DATE FOR KETAMINE PHARMATHER HOLDINGS LTD - FDA ASSIGNS JUNE 4, 2025 APPROVAL GOAL DATE FOR PHARMATHER'S KETAMINE NDA PHARMATHER HOLDINGS LTD: EXPECTING FDA APPROVAL OF KETAMINE ON OR BEFORE JUNE 4, 2025 Source text: nGNX449wLG Further company coverage: PHRM.CD ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application